Yahoo
NYSE - Nasdaq Real Time Price USD

Boston Scientific Corporation (BSX)

42.17 -0.26 (-0.62%)
As of 11:36:41 AM EDT. Market Open.
Trade BSX on Coinbase
BSX Q3 2026 earnings call
Replay the call for the latest insights.

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Michael F. Mahoney
Chairman, President & CEO 5.73M 25.79M 1965
Mr. Jonathan R. Monson
Executive VP & CFO 1.47M 1.71M 1974
Mr. Vance R. Brown J.D.
EVP, General Counsel & Corporate Secretary 1.6M -- 1970
Mr. Joseph M. Fitzgerald
Executive VP & Group President of Cardiovascular 2.4M 23.54M 1964
Mr. Arthur Crosswell Butcher
Executive VP and Group President of MedSurg & Asia Pacific 1.98M 5.38M 1971
Mr. Paudie O'Connor
Executive Vice President of Global Operations -- -- 1968
Ms. Emily M. Woodworth
Senior VP, Global Controller & Chief Accounting Officer -- -- 1978
Mr. Adam Smith
General Manager of Global Sales & Marketing -- -- --
Ms. Miriam O'sullivan
Senior VP & Chief Human Resources Officer -- -- 1981
Ms. Brenda Becker
Senior Vice President of Global Government Affairs -- -- 1960

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000 https://www.bostonscientific.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
59,000

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Boston Scientific Corporation’s ISS Governance QualityScore as of October 1, 2026 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 4; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 28, 2026 at 12:30 PM UTC

Boston Scientific Corporation Earnings Date

Recent Events

October 28, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 7, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 23, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 26, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 3, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 29, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 27, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 24, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

May 21, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: